Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

409 results about "Levofloxacin" patented technology

Levofloxacin is used to treat a variety of bacterial infections.

Method for determining 10 kinds of antibiotics in water environment through combination of sample pre-treatment technology and HPLC-MS

The present invention relates to a method for determining 10 kinds of antibiotics in a water environment through combination of a sample pre-treatment technology and HPLC-MS, and belongs to the field of detection of safety of trace organic contaminant residue in the water environment. The method is characterized in that a water sample is separated and enriched through combination of solid phase extraction and dispersive liquid-liquid microextraction (SPE-DLLME), and then an ultra-high performance liquid chromatography-mass spectrometry instrument (UPLC-MS/MS) is adopted as a detection tool to directly determine the contents of 10 kinds of common antibiotics in the water environment (drinking water, tap water, river water, sewage treatment plant influent and effluent), wherein the 10 kinds of the common antibiotics respectively are sulfadiazine, sulfamethoxazole, oxytetracycline, tetracycline, doxycycline, ciprofloxacin, levofloxacin, chloramphenicol, cefuroxime axetil and tinidazole. According to the present invention, the water sample pre-treatment method and the instrument detection conditions are investigated and optimized, and the optimal SPE-DLLME-UPLC-MS/MS method is established and is successfully applied for the real sample determination; and compared with the traditional method, the method of the present invention has advantages of high sensitivity, high extraction recovery rate, wide application objects, environmental protection, and the like.
Owner:SHENYANG PHARMA UNIVERSITY

Preparation process of lavo-ofloxacin and ofloxacin

The invention relates to a preparation process of lavo-ofloxacin and ofloxacin which are anti-infectious medicaments, belonging to the synthetic process with tetrafluorobenzoic aid as raw material. The preparation method is characterized in that (2, 3, 4, 5-phenyl tetrafluoride formyl) ethyl acetate and DMFA react for 1.0-1.5h in toluene at 50-55 DEG C with the existence of acylating catalyst; the reaction product is washed by water, and an aqueous layer is separated; at 30-35 DEG C, L-amino propanol is dripped in an oil layer to carry out replacement reaction for 1.5-2.0h; toluene is decompressed, recovered and dried proper quantity of DMF is added to the oil layer for diluting; the diluted oil layer is dripped into back-flow DMF with the existence of anhydrous potassium fluoride to carry out back-flow reaction for 6h; DMF is recovered, water is added for centrifugation, acid is added to the obtained solid to be hydrolyzed to prepare lavo-perfluorocarboxylic acid, the lavo-perfluorocarboxylic acid reacts with N-methyl piperazine in DMSO at 90-110 DEG C by taking triethylamine as an acid-binding agent, and the lavo-ofloxacin is obtained after the fine purification of the product of reaction. The process improves the reaction condition of (2, 3, 4, 5-phenyl tetrafluoride formyl) ethyl acetate and DMFA, lowers the reaction temperature, shortens the reaction time and improves the reaction yield of lavo-fluoro ester serving as a reaction intermediate by 20 percent.
Owner:HENAN TOPFOND PHARMA

Polyvinyl alcohol/sodium alginate medicine-loading hydrogel dressing having light-responsive bacteria resistance and preparation method of polyvinyl alcohol/sodium alginate medicine-loading hydrogel dressing

The invention relates to polyvinyl alcohol/sodium alginate medicine-loading hydrogel dressing having light-responsive bacteria resistance and a preparation method of the polyvinyl alcohol/sodium alginate medicine-loading hydrogel dressing, wherein a macromolecular medicine realizing fracturing under ultraviolet light is distributed inside the hydrogel dressing. The preparation method of the polyvinyl alcohol/sodium alginate medicine-loading hydrogel dressing comprises the following steps: grafting micromolecule antibiotic, namely, levofloxacin to polyethylene glycol macromolecular chains with amino groups at two ends through molecules with ultraviolet light response property, thus obtaining the macromolecular medicine realizing fracturing under ultraviolet light; and carrying out repeated freezing and thawing on a mixed solution of polyvinyl alcohol solution, sodium alginate solution and the macromolecular medicine realizing fracturing under ultraviolet light, thus obtaining the polyvinyl alcohol/sodium alginate medicine-loading hydrogel dressing having light-responsive bacteria resistance. The adopted raw materials have good biocompatibility, the obtained hydrogel dressing has certain mechanical property and has the ultraviolet-light-responsive antibacterial property, namely, the hydrogel dressing can realize controlled release of antibiotics under irradiation of 365nm ultraviolet light, and thus the polyvinyl alcohol/sodium alginate medicine-loading hydrogel dressing is suitable for protecting and treating the wound surface.
Owner:ZHEJIANG UNIV

Long-acting sustained-release wound dressing containing levofloxacin sustained-release microspheres, and preparation method thereof

The invention discloses a long-acting sustained-release wound dressing containing levofloxacin sustained-release microspheres. According to the preparation method of the wound dressing, levofloxacin sustained-release microspheres with grain diameter between 10 and 20mu m are fixed in a composite medical non-woven fabric which mainly comprises chitosan fiber, alginate fiber, viscose fiber, and hydrophobic ethylene propylene fiber; and the long-acting sustained-release wound dressing is prepared by taking the levofloxacin sustained-release microspheres as a medicinal component. In a use process, the medicament quickly release levofloxacin after contacting the blood, tissues and surrounding skin of the wound, and can continuously release levofloxacin for a long time, and the effective release of levofloxacin accumulatively reaches 168h. The long-acting sustained-release wound dressing is applied to treatment of bacterium infection of burnt and scalded skin, and the microsphere state medicament can remarkably improve the bioavailability of effective components of the medicament; and the long-acting sustained-release wound dressing has excellent moisture penetrability, hygroscopicity, mechanical tensile property and biocompatibility, the frequency of dressing change can be reduced, and the curative effect and administration safety cam be enhanced.
Owner:SANITARY EQUIP INST ACAD OF MILITARY MEDICAL SCI PLA

Eye in-situ gel of chiral anti-glaucoma medicine L-3alpha alkyla acyloxy-6belta alkyla acyloxy tropane and preparation method thereof

The invention relates to an ophthalmic in-situ jelly of chiral anti-glaucoma medicine levofloxacin tropane. The ophthalmic jellies concretely comprises 0.03 percent to 0.3 percent of levofloxacin tropane, 10 percent to 20 percent of hydrophilic polymer material, 0 percent to 20 percent of humectant, 0.1 percent to 10 percent of permeation pressure regulator, 0.01 percent to 0.3 percent of antiseptic/bacteriostat, pH value regulator and water. In a preparation method, the materials are weighted according to the percentage; the levofloxacin tropane is solved in injection water, the hydrophilic polymer material is added under the stirring state, and the solution is stood over a night; the adjuvant such as the humectant and the like is added, and the pH value is adjusted as 4 to 9; the solution is filtered, the injection water is added to the total quantity, and the ophthalmic in-situ jelly is obtained. The ophthalmic in-situ jelly has the advantages of uniform and smooth quality, proper viscosity, convenient use, exact dosage, and long-term uniform distribution on the surface of eye cornea; besides, the jelly causes no hypersusceptibility and irritation, no blurred vision, can effectively prolong the acting time of the medicine on the eye cornea, and has wide application prospect.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE

Insoluble magnetic cobalt/defective g-C3N4 composite catalyst and application thereof to catalytic Oxone wastewater degradation

The invention discloses an insoluble magnetic cobalt/defective g-C3N4 composite catalyst and application thereof to catalytic Oxone wastewater degradation, and belongs to the technical field of composite catalytic material synthesis and organic wastewater catalytic degradation. The composite catalyst is characterized in that a preparation method of the insoluble magnetic cobalt/defective g-C3N4 composite catalyst concretely comprises the steps of preparation of magnetic cobalt catalysts with the cobalt mass percentage content being 11 percent, preparation of insoluble magnetic cobalt/defectiveg-C3N4 composite catalysts with the cobalt mass percentage content being 1.2 percent and the like. The insoluble magnetic cobalt/defective g-C3N4 composite catalyst can be used for efficiently catalyzing Oxone to degrade levofloxacin wastewater. The prepared insoluble magnetic cobalt/defective g-C3N4 composite catalyst has better infusibility in neutral environment; meanwhile, better catalytic performance is realized; certain photocatalytic performance is also realized; the insoluble magnetic cobalt/defective g-C3N4 composite catalyst can be applied to the degradation of nonbiodegradable organic pollutants.
Owner:HENAN NORMAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products